Skip to content

Claim analyzed

Health

“At week 72 of the Phase 3 SURMOUNT-1 trial, the mean percentage change in body weight was -20.9% with once-weekly 5 mg tirzepatide.”

The conclusion

False
1/10

The claim assigns the 15 mg dose's weight-loss result to the 5 mg dose. At week 72 of the Phase 3 SURMOUNT-1 trial, mean body-weight change was −15.0% with once-weekly 5 mg tirzepatide; −20.9% was the result for 15 mg. The peer-reviewed trial report and FDA records, including the January 2026 label, consistently document this distinction.

Suggested rewrite

At week 72 of the Phase 3 SURMOUNT-1 trial, the mean percentage change in body weight was -15.0% with once-weekly 5 mg tirzepatide.

Caveats

  • The reported percentages are group means, not guaranteed outcomes for individual patients.
  • The trial publication and FDA records describe the same underlying trial, not independent clinical replications.

This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.

Sources

Ranked by source quality and relevance

#1
nejm.org 2022-06-04 | Tirzepatide Once Weekly for the Treatment of Obesity | New England Journal of Medicine

The mean percentage change in weight at week 72 was −15.0% (95% confidence interval [CI], −15.9 to −14.2) with 5-mg weekly doses of tirzepatide, −19.5% (95% CI, −20.4 to −18.5) with 10-mg doses, and −20.9% (95% CI, −21.8 to −19.9) with 15-mg doses and −3.1% (95% CI, −4.3 to −1.9) with placebo (P<0.001 for all comparisons with placebo).Results At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was −15.0% (95% confidence interval [CI], −15.9 to −14.2) with 5-mg weekly doses of tirzepatide, −19.5% (95% CI, −20.4 to −18.5) with 10-mg doses, and −20.9% (95% CI, −21.8 to −19.9) with 15-mg doses and −3.1% (95% CI, −4.3 to −1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). …

#2
accessdata.fda.gov 2026-01-01 | Revised: 01/2026

Study 1 (NCT04184622) was a 72-week trial that enrolled 2,539 adult patients with obesity (BMI ≥30 kg/m 2), or with overweight (BMI 27 to <30 kg/m 2) and at least one weight-related comorbid condition, such as dyslipidemia, hypertension, obstructive sleep apnea, or cardiovascular disease; patients with type 2 diabetes mellitus were excluded. … Table 2: Changes in Body Weight at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight Intention-to-Treat (ITT) Population · ZEPBOUND Placebo a N = 643 · 5 mg N = 630 · Study 1 ZEPBOUND · 10 mg N = 636 · ZEPBOUND · 15 mg N = 630 · Placebo N = 315 · ZEPBOUND · Study 2 10 mg N = 312 · ZEPBOUND · 15 mg N = 311 Body Weight Baseline mean (kg) · 104.8 · 102.9 · 105.8 · 105.6 · 101.7 · 100.9 · 99.6 % Change from b baseline · -3.1 · -15.0 · -19.5 · -20.9 · -3.2 · -12.8 · -14.7… a reduced-calorie diet (approximately 500 kcal/day deficit) and increased physical activity counseling (recommended minimum of 150 min/week) that began with the first dose of study medication or placebo and continued throughout the trial. Patients also received counseling on behavior modification strategies to adhere to diet and exercise recommendations. In both trials, weight reduction was assessed after 72 weeks of treatment (at least 52 weeks at maintenance dose). Study 1 (NCT04184622) was a 72-week trial that enrolled 2,539 adult patients with obesity (BMI ≥30 kg/m 2), or with overweight (BMI 27 to <30 kg/m 2) and at least one weight-related comorbid condition, such as dyslipidemia, hypertension, obstructive sleep apnea, or cardiovascular disease; patients with type 2 diabetes mellitus were excluded. Patients were randomized in a 1:1:1:1 ratio to once weekly fixed dosage of ZEPBOUND 5 mg, ZEPBOUND 10 mg, ZEPBOUND 15 mg, or placebo, with an escalation period of up to 20 weeks followed by the maintenance period. At baseline, mean age was 45 years (range 18-84 years), 68% were female, 71% were White, 11% were Asian, 9% were American Indian/Alaska Native, and 8% were Black or African American. A total of 48% were Hispanic or Latino ethnicity. … Among patients treated with ZEPBOUND 10 mg and 15 mg, greater proportions of patients achieved at least 10%, 15%, and 20% weight reduction compared to placebo (see Table 2). A reduction in body weight was observed with ZEPBOUND irrespective of age, sex, race, ethnicity, baseline BMI, and glycemic status. Table 2: Changes in Body Weight at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight Intention-to-Treat (ITT) Population · ZEPBOUND Placebo a N = 643 · 5 mg N = 630 · Study 1 ZEPBOUND · 10 mg N = 636 · ZEPBOUND · 15 mg N = 630 · Placebo N = 315 · ZEPBOUND · Study 2 10 mg N = 312 · ZEPBOUND · 15 mg N = 311 Body Weight Baseline mean (kg) · 104.8 · 102.9 · 105.8 · 105.6 · 101.7 · 100.9 · 99.6 % Change from b baseline · -3.1 · -15.0 · -19.5 · -20.9 · -3.2 · -12.8 · -14.7 % Difference from · (-13.4, -10.4) · -11.9 · d (-17.9, -14.8) · -16.4 · d (-19.3, -16.3) · -17.8 · d · (-11.1, -8.1) · -9.6 · d · -11.6 b placebo · (-13.0, -10.1) · d (95% CI) % of Patients losing ≥5% body weight · 34.5 · 85.1 · 88.9 · 90.9 · 32.5 · 79.2 · 82.8 % Difference from placebo (95% CI) · (44.3, 56.2) · 50.3 c,d · (49.1, 60.0) · 54.6 c,d · (50.9, 62.0) · 56.4 c,d · (39.5, 54.1) · 46.8 c,d · (43.1, 57.8) · 50.4 c,d · …

#3
doi.org 2025-11-06 | Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial

The mean change in weight at week 72 was -15.0% (95% CI -15.9% to -14.2%) with a 5-mg weekly dose of tirzepatide, -19.5% (95% CI -20.4% to -18.5%) with a 10-mg dose, -20.9% (95% CI -21.8% to -19.9%) with a 15-mg dose, and -3.1% (95% CI -4.3% to -1.9%) with placebo, as reported in Figure 1 .Change in body weight The mean change in weight at week 72 was -15.0% (95% CI -15.9% to -14.2%) with a 5-mg weekly dose of tirzepatide, -19.5% (95% CI -20.4% to -18.5%) with a 10-mg dose, -20.9% (95% CI -21.8% to -19.9%) with a 15-mg dose, and -3.1% (95% CI -4.3% to -1.9%) with placebo, as reported in Figure 1 . Change in SUA levels

#4
accessdata.fda.gov 2023-10-10 | 217806Orig1s000

Table 14: Key Secondary Endpoints in SURMOUNT-1 (at Week 72) SURMOUNT-1 · Tirzepatide 5 mg N=630 · Placebo N=643 %Change in body weight Baseline body weight (kg), mean (SD) · 102.9 (20.7) · 104.8 (21.4) Estimate, LSMean (SE)1 · -15.0 (0.4) · -3.1 (0.6)Tirzepatide 5 mg achieved superiority compared with placebo for %change in body weight and the proportions of subjects who had at least 5% body weight reduction from baseline to Week 72 (Table 14). Table 14: Key Secondary Endpoints in SURMOUNT-1 (at Week 72) SURMOUNT-1 · Tirzepatide 5 mg N=630 · Placebo N=643 %Change in body weight Baseline body weight (kg), mean (SD) · 102.9 (20.7) · 104.8 (21.4) Estimate, LSMean (SE)1 · -15.0 (0.4) · -3.1 (0.6) Difference from placebo (95% CI) · -11.9 (-13.4, -10.4) P-value · <0.001 Missing, n(%) · 64 (10.2) · 139 (21.6) 5% Body weight loss Proportion estimate2 · 85.5 · 34.0 Difference from placebo (95% CI) · 51.5 (45.7, 57.4) P-value · <0.001 Missing, n(%) · 64 (10.2) · 139 (21.6)

#5
ovid.com 2022-07-21 | Tirzepatide Once Weekly for the Treatment of... : New England Journal of Medicine

The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo).RESULTS At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). …

#6
pubmed.ncbi.nlm.nih.gov 2022-07-21 | Tirzepatide Once Weekly for the Treatment of Obesity

The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo).… Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. Results: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). …

#7
acc.org 2024-12-23 | Tirzepatide Once Weekly for the Treatment of Obesity - American College of Cardiology

The co-primary endpoint, percentage change in body weight from baseline to week 72, for tirzepatide vs. placebo (p < 0.001): - 5 mg: −15% - 10 mg: −19.5% - 15 mg: −20.9% - Placebo: −3.1%Principal Findings: The co-primary endpoint, percentage change in body weight from baseline to week 72, for tirzepatide vs. placebo (p < 0.001): - 5 mg: −15% - 10 mg: −19.5% - 15 mg: −20.9% - Placebo: −3.1% The co-primary endpoint, a weight reduction of ≥5% at week 72, for tirzepatide vs. placebo (p < 0.001):

#8
aafp.org 2023-01-15 | Tirzepatide Helps Adults With Obesity Without Diabetes Lose 15% to 21% of Their Body Weight Over 72 Weeks | AFP

The reduction in weight was 15% in the 5-mg group, 19.5% in the 10-mg group, 20.9% in the 15-mg group, and 3.1% in the placebo group.… Patients with diabetes were excluded. The mean age of the 2,539 patients was 45 years, 67% were women, and 60% had a body mass index greater than 35.0 kg per m 2. Allocation concealment was not described, but groups were balanced at the start of the study. The patients were randomized to receive 5, 10, or 15 mg of tirzepatide or matching placebo injection once weekly. Approximately 86% of participants completed the 72-week study. The reduction in weight was 15% in the 5-mg group, 19.5% in the 10-mg group, 20.9% in the 15-mg group, and 3.1% in the placebo group. Reductions also occurred in metabolic markers, such as systolic blood pressure (6.2 mm Hg) and low-density lipoprotein cholesterol (4.2 mg per dL [0.15 mmol per L]), in the tirzepatide groups. Serious adverse events were rare and evenly distributed among groups. Discontinuation due to adverse events was 2.6% in the placebo group and 4.3% to 7.1% in the tirzepatide groups. Study design: Randomized controlled trial (double-blinded)

#9
doi.org 2022-11-02 | Tirzepatide Reduced Significantly the Body Weight in Obese Patients

The results of the 72-week long trial are shown in Table 1. The mean body weight at the beginning of the trial was 104.4 kg. The percentage weight loss of patients treated with 5-10-15 mg Tirzepatide, respectively, were 15 %, 19.5 % and 20.9 %, while 3.1 % in the placebo group.… Indeed, the loss of more than 20% of body weight during a 72-week long trial surpasses the results of all other earlier drugs and investigations. The author demonstrates the results of the SURMOUNT-1 study.Patients The 2539 patients were divided into four groups, receiving 5, 10 and 15 mg Tirzepatide or placebo as subcutaneous injection once in a week, respectively. Patients were also educated for appropriate diet by a dietitian and exercised for at least 150 minutes per week. Results The results of the 72-week long trial are shown in Table 1. The mean body weight at the beginning of the trial was 104.4 kg. The percentage weight loss of patients treated with 5-10-15 mg Tirzepatide, respectively, were 15 %, 19.5 % and 20.9 %, while 3.1 % in the placebo group. The deviation to the placebo group were 11 % (13.4 % -10.4 %), 16.4 % (17.9 % -14.8 %) and 17.8 % (19.3-% -16.3 %) at p<0,001 for patients given 5-10-15 mg Tirzepatide, respectively. At the end of 72 weeks, the percentage of patients losing 20% body weight, or more were significantly higher in the Tirzepatide group (p<0,001). …

#10
doi.org 2022-09-23 | Tirzepatide: A New Anti-Obesity Medication

The mean changes in weight by week 72 were 15% (95% CI 14.2%-15.9%), 19.5% (18.5%-20.4%), 20.9% (19.9%-21.8%), and 3.1% (1.9%-4.3%) with 5 mg, 10 mg, 15 mg, and placebo, respectively.… The primary end point was percentage change in body weight from baseline to week 72. Secondary end points included weight reduction by 10%, 15%, or 20% or more by week 72. The mean age of participants was 45 years, with 69% female and 71% white. The mean body weight and BMI at baseline were 105 kg and 38 kg/m 2, respectively. The mean changes in weight by week 72 were 15% (95% CI 14.2%-15.9%), 19.5% (18.5%-20.4%), 20.9% (19.9%-21.8%), and 3.1% (1.9%-4.3%) with 5 mg, 10 mg, 15 mg, and placebo, respectively. At week 72, 50% and 57% of participants in the 10 mg and 20 mg tirzepatide groups had 20% reduction in body weight, compared with 3% with placebo. The intervention group had significant improvements in cardiometabolic risk factors (waist circumference, systolic and diastolic blood pressure, fasting insulin, lipid and aspartate transaminase levels). …

#11
accessdata.fda.gov 2023-11-08 | 217806Orig1s000 SUMMARY REVIEW

Change in mean percent weight reduction from baseline to Week 72, placebo • adjusted treatment difference Patients without diabetes o ▪ Tirzepatide 5 mg: -11.9% (-13.4%, -10.4%) ▪ Tirzepatide 10 mg: -16.4% (-17.9%, -14.8%) ▪ Tirzepatide 15 mg: -17.8% (-19.3%, -16.3%) … Table 2 summarizes the percent change in body weight and proportion of patients losing at least 5% body weight loss for tirzepatide 5 mg; both endpoints were key secondary endpoints controlled for Type 1 error.… Lifestyle intervention is not effective in most patients. GLP-1 RAs are increasingly prescribed for chronic weight management based on improved treatment effect and evidence of cardiovascular benefit in a related population. The cardiovascular benefit of pharmacologic-induced weight loss has not yet been demonstrated in clinical trials to date. Benefit · Change in mean percent weight reduction from baseline to Week 72, placebo • adjusted treatment difference Patients without diabetes o ▪ Tirzepatide 5 mg: -11.9% (-13.4%, -10.4%) ▪ Tirzepatide 10 mg: -16.4% (-17.9%, -14.8%) ▪ Tirzepatide 15 mg: -17.8% (-19.3%, -16.3%) Patients with diabetes o ▪ Tirzepatide 10 mg: -9.6% (-11.1%, -8.1%) ▪ Tirzepatide 15 mg: -11.6% (-13.0%, -10.1%) Proportion of subjects achieving a clinically meaningful threshold of weight • reduction (at least 5%) from baseline to Week 72 · The two randomized, placebo-controlled phase 3 clinical trial results represent substantial evidence of effectiveness that tirzepatide 5 mg, 10 mg, and 15 mg injections result in clinically meaningful weight loss and improvement in cardiometabolic … Table 1. Primary Endpoint Results, Tirzepatide 10 mg and 15 mg, SURMOUNT-1 The FDA statistical reviewer, Dr. Song, confirmed the results of the co-primary endpoints and concluded that the multiple prespecified sensitivity analyses were consistent with the primary analysis. Additionally, she concluded that tipping point analyses supported the robustness of the conclusion derived from the primary analysis. Refer to the FDA statistical review for additional details. Table 2 summarizes the percent change in body weight and proportion of patients losing at least 5% body weight loss for tirzepatide 5 mg; both endpoints were key secondary endpoints controlled for Type 1 error. Results were statistically significant and clinically meaningful. Table 2. Weight-Related Endpoints, Tirzepatide 5 mg, SURMOUNT-1 Table 3 summarizes the first four secondary endpoints in the testing hierarchy, the proportions of patients achieving ≥10%, ≥15%, and ≥20% body weight loss from baseline and change in waist circumference for tirzepatide 10 mg and 15 mg doses. Figure 1 presents the cumulative distribution for percent change in body weight by treatment arm. Table 3. …

#12
va.gov 2023-12 | Tirzepatide (ZEPBOUND) Subcutaneous Injection for Chronic Weight Management National Drug Monograph December 2023

Compared to placebo, treatment with tirzepatide SC injection once weekly also resulted in a significant reduction in the coprimary endpoint of percentage weight reduction from baselineof 15.0%, 19.5%, and 20.9% with doses of 5 mg, 10 mg and 15 mg, respectively (vs. 3.1% reduction with placebo).… In the STEP 1 placebo-controlled trial, approximately 86% of patients treated with semaglutide (WEGOVY) 2.4 mg weekly achieved >= 5% reduction in weight. In the SURMOUNT-1 weight management trial with tirzepatide, 85%, 89% and 91% of patients achieved >= 5% reduction in weight on the 5 mg, 10 mg, and 15 mg weekly doses, respectively. Compared to placebo, treatment with tirzepatide SC injection once weekly also resulted in a significant reduction in the coprimary endpoint of percentage weight reduction from baselineof 15.0%, 19.5%, and 20.9% with doses of 5 mg, 10 mg and 15 mg, respectively (vs. 3.1% reduction with placebo). As one of the key secondary endpoints, approximately 57% of patients receiving tirzepatide 15 mg weekly achieved >= 20% reduction in body weight. SURMOUNT-2 evaluated tirzepatide for weight management in patients with type 2 DM and 79% (10 mg weekly) to 83% (15 mg weekly) of patients achieved weight reduction of >= 5%. …

#13
tctmd.com 2022-06-09 | SURMOUNT-1: Tirzepatide Drastically Reduces Weight in Obese Patients

At 72 weeks, the mean reduction in body weight was 15% in the 5-mg group, 19.5% in the 10-mg group, 20.9% in the 15-mg group, and 3.1% in the placebo group.… Baseline weight was approximately 231 pounds. All also were required to have been unsuccessful in one or more diet attempts. Tirzepatide or placebo were initially started at 2.5 mg once weekly and increased by 2.5 mg every 4 weeks during a dose-escalation period to reach a maintenance dose of up to 15 mg a week by week 20. At 72 weeks, the mean reduction in body weight was 15% in the 5-mg group, 19.5% in the 10-mg group, 20.9% in the 15-mg group, and 3.1% in the placebo group. In pounds lost, those changes translated to 35.5, 48.9, 52.0, and 5.3, respectively. Overall, more than 90% of those on tirzepatide 15 mg achieved the co-primary endpoint of weight reduction of 5% or more. Nearly 60% achieved a target of 20% or greater reduction in weight from baseline, and about one-third had a reduction of 25% or more. At both the 10- and 15-mg doses, nearly all patients lost weight, with an expected heterogeneity in response among participants.

#14
healio.com 2022-06-04 | Weekly tirzepatide confers substantial weight loss in obesity without diabetes: SURMOUNT-1

At 72 weeks, mean percentage change in weight was –15% with the 5 mg tirzepatide dose (95% CI, –15.9 to –14.2), –19.5% with the 10 mg dose (95% CI, –20.4 to –18.5), –20.9% with the 15 mg dose (95% CI, –21.8 to –19.9) and 3.1% with placebo (95% CI, –4.3 to –1.9; P < .001 for all comparisons with placebo).At baseline, mean body weight was 104.8 kg; mean BMI was 38 kg/m 2. At 72 weeks, mean percentage change in weight was –15% with the 5 mg tirzepatide dose (95% CI, –15.9 to –14.2), –19.5% with the 10 mg dose (95% CI, –20.4 to –18.5), –20.9% with the 15 mg dose (95% CI, –21.8 to –19.9) and 3.1% with placebo (95% CI, –4.3 to –1.9; P < .001 for all comparisons with placebo). The placebo-subtracted difference for the 15 mg group was 17.8 percentage points, Jastreboff said during a presentation. “There was a relatively similar weight reduction for the 10 mg and 15 mg groups, at least on average,” Jastreboff said.

#15
healio.com 2022-04-28 | Adults achieve weight loss of 16% or more at 72 weeks with tirzepatide

Adults randomly assigned to receive tirzepatide had a mean weight loss of 16% with 5 mg, 21.4% with 10 mg, and 22.5% with 15 mg compared with a 2.4% mean weight loss for those assigned placebo.Perspectives from Scott Kahan, MD, MPH; W. Timothy Garvey, MD, FACE In a phase 3 trial with 2,539 participants, tirzepatide (Eli Lilly) met both primary endpoints for mean percentage change in body weight from baseline and percentage of participants with a 5% reduction in body weight compared with placebo. Adults randomly assigned to receive tirzepatide had a mean weight loss of 16% with 5 mg, 21.4% with 10 mg, and 22.5% with 15 mg compared with a 2.4% mean weight loss for those assigned placebo. Of those assigned tirzepatide, 89% achieved a weight loss of at least 5% compared with 28% in the placebo group. Aronne is the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine at New York-Presbyterian/Weill Cornell Medical Center and investigator in the SURMOUNT-1 trial.

#16
patientcareonline.com 2022-06-04 | Tirzepatide Treatment Leads to Weight Loss of up to 22.5% in SURMOUNT-1 Clinical Trial

The mean percentage change in weight at week 72 for the 3 tirzepatide doses was (% / 95% CI): - 5 mg:** −15.0%** (−15.9 to −14.2) - 10 mg: −19.5% (−20.4 to −18.5) - 15 mg: −20.9% (−21.8 to −19.9) - Placebo: −3.1% (−4.3 to −1.9)Overall, SURMOUNT-1 participants who received terzepatide lost between 16% and 22.5% of their baseline body weight. The mean percentage change in weight at week 72 for the 3 tirzepatide doses was (% / 95% CI): - 5 mg:** −15.0%** (−15.9 to −14.2) - 10 mg: −19.5% (−20.4 to −18.5) - 15 mg: −20.9% (−21.8 to −19.9) - Placebo: −3.1% (−4.3 to −1.9) All comparisons with placebo for change in weight were statistically significnant (P<.001). Percentage of participants meeting the coprimary end point of weight reduction ≥5% are shown at right.

#17
investor.lilly.com 2022-04-28 | Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 | Eli Lilly and Company

For the efficacy estimand, participants taking tirzepatide achieved average weight reductions of 16.0% (35 lb. or 16 kg on 5 mg), 21.4% (49 lb. or 22 kg on 10 mg) and 22.5% (52 lb. or 24 kg on 15 mg), compared to placebo (2.4%, 5 lb. or 2 kg). … - Average body weight reductions: 15.0% (5 mg), 19.5% (10 mg), 20.9% (15 mg), 3.1% (placebo)… Tirzepatide met both co-primary endpoints of superior mean percent change in body weight from baseline and greater percentage of participants achieving body weight reductions of at least 5% compared to placebo for both estimands ii. The study also achieved all key secondary endpoints at 72 weeks. For the efficacy estimand, participants taking tirzepatide achieved average weight reductions of 16.0% (35 lb. or 16 kg on 5 mg), 21.4% (49 lb. or 22 kg on 10 mg) and 22.5% (52 lb. or 24 kg on 15 mg), compared to placebo (2.4%, 5 lb. or 2 kg). Additionally, 89% (5 mg) and 96% (10 mg and 15 mg) of people taking tirzepatide achieved at least 5% body weight reductions compared to 28% of those taking placebo. In a key secondary endpoint, 55% (10 mg) and 63% (15 mg) of people taking tirzepatide achieved at least 20% body weight reductions compared to 1.3% of those taking placebo. In an additional secondary endpoint not controlled for type 1 error, 32% of participants taking tirzepatide 5 mg achieved at least 20% body weight reductions. … For the treatment-regimen estimand iii, results showed: - Average body weight reductions: 15.0% (5 mg), 19.5% (10 mg), 20.9% (15 mg), 3.1% (placebo) - Percentage of participants achieving body weight reductions of ≥5%: 85% (5 mg), 89% (10 mg), 91% (15 mg), 35% (placebo) - Percentage of participants achieving body weight reductions of ≥20%: 30% (5 mg, not controlled for type 1 error), 50% (10 mg), 57% (15 mg), 3.1% (placebo) The overall safety and tolerability profile of tirzepatide was similar to other incretin-based therapies approved for the treatment of obesity. …

#18
investor.lilly.com 2022-06-04 | Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight | Eli Lilly and Company

For the efficacy estimand ii, participants taking tirzepatide achieved average weight reductions of 16.0% (35 lb. or 16 kg on 5 mg), 21.4% (49 lb. or 22 kg on 10 mg) and 22.5% (52 lb. or 24 kg on 15 mg), compared to placebo (2.4%, 5 lb. or 2 kg). … Tirzepatide also met the co-primary and all key secondary endpoints for the treatment-regimen estimand iii, including: - Average body weight reductions: 15.0% (5 mg), 19.5% (10 mg) and 20.9% (15 mg) compared to 3.1% with placebo.82 nd Scientific Sessions ®. Tirzepatide met both co-primary endpoints of superior mean percent change in body weight from baseline and greater percentage of participants achieving body weight reductions of at least 5% compared to placebo for both estimands i. For the efficacy estimand ii, participants taking tirzepatide achieved average weight reductions of 16.0% (35 lb. or 16 kg on 5 mg), 21.4% (49 lb. or 22 kg on 10 mg) and 22.5% (52 lb. or 24 kg on 15 mg), compared to placebo (2.4%, 5 lb. or 2 kg). Additionally, 89% (5 mg) and 96% (10 mg and 15 mg) of people taking tirzepatide achieved at least 5% body weight reductions compared to 28% of those taking placebo. All three doses of tirzepatide achieved all key secondary endpoints at 72 weeks of treatment for the efficacy estimand, including: … . "In SURMOUNT-1, participants taking tirzepatide on average lost up to one fifth of their body weight – and notably, about nine out of ten participants taking tirzepatide lost weight. These results are significantly higher than the placebo arm and underscore the importance of this study." Tirzepatide also met the co-primary and all key secondary endpoints for the treatment-regimen estimand iii, including: - Average body weight reductions: 15.0% (5 mg), 19.5% (10 mg) and 20.9% (15 mg) compared to 3.1% with placebo. - Percentage of participants achieving body weight reductions of ≥5%: 85% (5 mg), 89% (10 mg) and 91% (15 mg) compared to 35% with placebo. - Percentage of participants achieving ≥10% body weight reductions: 69% (5 mg, not controlled for type 1 error), 78% (10 mg) and 84% (15 mg) compared to 19% with placebo. - Percentage of participants achieving ≥15% body weight reductions: 48% (5 mg, not controlled for type 1 error), 67% (10 mg) and 71% (15 mg) compared to 9% with placebo. …

#19
zepbound.lilly.com Clinical Data, Safety & Study Design | Zepbound® (tirzepatide)

The observed mean percentage change in body weight at 72 weeks post randomization was -15.0% for Zepbound 5 mg, -19.5% for Zepbound 10 mg, and -20.9% for Zepbound 15 mg vs -3.1% for placebo.… There were 566, 569, 571, and 504 total adults given Zepbound 5 mg, 10 mg, 15 mg, and placebo, respectively, at 72 weeks. There were 630, 636, 630, and 643 total adults given Zepbound 5 mg, 10 mg, 15 mg, and placebo, respectively, at 72 weeks with hybrid imputation. The mean baseline weights were 226.8 lb for Zepbound 5 mg, 233.3 lb for Zepbound 10 mg, 232.8 lb for Zepbound 15 mg, and 231.0 lb for placebo. The observed mean percentage change in body weight at 72 weeks post randomization was -15.0% for Zepbound 5 mg, -19.5% for Zepbound 10 mg, and -20.9% for Zepbound 15 mg vs -3.1% for placebo. text efficacy_section

#20
clinicaltrials.gov NCT04184622 | A Study of Tirzepatide (LY3298176) in Participants With ...

* Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 milligrams (mg) and increasing by 2.5 mg every 4 weeks until reaching a dose of 5 mg, which was then maintained up to week 72. … ### Percent Change From Baseline in Body Weight (Primary Treatment Period) Least Squares (LS) Mean was calculated using mixed-model repeated measures (MMRM) with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model. Time frame: Baseline, Week 725 mg Tirzepatide (EXPERIMENTAL) * Primary Treatment Period (Week 0-Week 72): Participants with normoglycemia or prediabetes at the time of randomization received QW SC doses of tirzepatide, starting at 2.5 milligrams (mg) and increasing by 2.5 mg every 4 weeks until reaching a dose of 5 mg, which was then maintained up to week 72. * Additional Treatment Period (Week 72-Week 176): At week 72, only participants who had prediabetes at the time of randomization and had completed the primary treatment period continued receiving the 5 mg tirzepatide dose SC QW until week 176. … ## Primary Outcomes Percent Change From Baseline in Body Weight (Primary Treatment Period) Least Squares (LS) Mean was calculated using mixed-model repeated measures (MMRM) with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model. Time frame: Baseline, Week 72 Percentage of Participants Who Achieve ≥5% Body Weight Reduction (Primary Treatment Period)

#21
vertexaisearch.cloud.google.com 2022-06-04 | Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight

For the efficacy estimandii, participants taking tirzepatide achieved average weight reductions of 16.0% (35 lb. or 16 kg on 5 mg), 21.4% (49 lb. or 22 kg on 10 mg) and 22.5% (52 lb. or 24 kg on 15 mg), compared to placebo (2.4%, 5 lb. or 2 kg). … Average body weight reductions: 15.0% (5 mg), 19.5% (10 mg) and 20.9% (15 mg) compared to 3.1% with placebo.… and presented in a symposium sponsored by the American Diabetes Association® (ADA) during the ADA's 82nd Scientific Sessions®. Tirzepatide met both co-primary endpoints of superior mean percent change in body weight from baseline and greater percentage of participants achieving body weight reductions of at least 5% compared to placebo for both estimandsi. For the efficacy estimandii, participants taking tirzepatide achieved average weight reductions of 16.0% (35 lb. or 16 kg on 5 mg), 21.4% (49 lb. or 22 kg on 10 mg) and 22.5% (52 lb. or 24 kg on 15 mg), compared to placebo (2.4%, 5 lb. or 2 kg). Additionally, 89% (5 mg) and 96% (10 mg and 15 mg) of people taking tirzepatide achieved at least 5% body weight reductions compared to 28% of those taking placebo. All three doses of tirzepatide achieved all key secondary endpoints at 72 weeks of treatment for the efficacy estimand, including: Percentage of participants achieving at least 10% body weight reductions: 73% (5 mg, not controlled for type 1 error), 86% (10 mg) and 90% (15 mg) compared to 14% with placebo. … Center for Weight Management. "In SURMOUNT-1, participants taking tirzepatide on average lost up to one fifth of their body weight – and notably, about nine out of ten participants taking tirzepatide lost weight. These results are significantly higher than the placebo arm and underscore the importance of this study." Tirzepatide also met the co-primary and all key secondary endpoints for the treatment-regimen estimandiii, including: Average body weight reductions: 15.0% (5 mg), 19.5% (10 mg) and 20.9% (15 mg) compared to 3.1% with placebo. Percentage of participants achieving body weight reductions of ≥5%: 85% (5 mg), 89% (10 mg) and 91% (15 mg) compared to 35% with placebo. Percentage of participants achieving ≥10% body weight reductions: 69% (5 mg, not controlled for type 1 error), 78% (10 mg) and 84% (15 mg) compared to 19% with placebo. Percentage of participants achieving ≥15% body weight reductions: 48% (5 mg, not controlled for type 1 error), 67% (10 mg) and 71% (15 mg) compared to 9% with placebo. …

#22
cardionerds.com 2022-09-07 | SURMOUNT-1 Trial

- Treatment-regimen estimand, the mean change in weight at week 72 was: - −15.0% (95% CI, −15.9 to −14.2) with a 5-mg weekly dose of tirzepatide - −19.5% (95% CI, −20.4 to −18.5) with a 10-mg dose - −20.9% (95% CI, −21.8 to −19.9) with a 15-mg dose … - Efficacy estimand, the mean change in weight at week 72 with tirzepatide was: - −16.0% (95% CI, −16.8 to −15.2), a weight reduction of 16.1 kg (35.5 lb), with the 5-mg dose - −21.4% (95% CI, −22.2 to −20.6), a reduction of 22.2 kg (48.9 lb), with the 10-mg dose - −22.5% (95% CI, −23.3 to −21.7), a reduction of 23.6 kg (52.0 lb) with the 15-mg dosea. Percentage weight change at week 72: - Treatment-regimen estimand, the mean change in weight at week 72 was: - −15.0% (95% CI, −15.9 to −14.2) with a 5-mg weekly dose of tirzepatide - −19.5% (95% CI, −20.4 to −18.5) with a 10-mg dose - −20.9% (95% CI, −21.8 to −19.9) with a 15-mg dose - −3.1% (95% CI, −4.3 to −1.9) with placebo - Estimated treatment differences relative to placebo of: - −11.9 percentage points (95% CI, −13.4 to −10.4) for the 5-mg dose - −16.4 percentage points (95% CI, −17.9 to −14.8) for the 10-mg dose - −17.8 percentage points (95% CI, −19.3 to −16.3) for the 15-mg dose - P<0.001 for all comparisons - Efficacy estimand, the mean change in weight at week 72 with tirzepatide was: - −16.0% (95% CI, −16.8 to −15.2), a weight reduction of 16.1 kg (35.5 lb), with the 5-mg dose - −21.4% (95% CI, −22.2 to −20.6), a reduction of 22.2 kg (48.9 lb), with the 10-mg dose - −22.5% (95% CI, −23.3 to −21.7), a reduction of 23.6 kg (52.0 lb) with the 15-mg dose - Mean change with placebo was −2.4% (95% CI, −3.2 to−1.6), a reduction of 2.4 kg (5.3 lb) - Corresponding estimated treatment differences with tirzepatide relative to placebo were: - −13.5 percentage points (95% CI, −14.6 to −12.5) for 5-mg dose - −18.9 percentage points (95% CI, −20.0 to −17.8) for 10-mg dose - −20.1 percentage points (95% CI, −21.2 to −19.0) for 15-mg dose b. Weight reduction of 5% or more at week 72:

#23
biomedabstracts.org 2026-08-19 | SURMOUNT-1: Tirzepatide Achieves Up to 20.9% Weight Loss in Phase 3 Obesity Trial

At 72 weeks, the mean weight change was −15.0% with 5 mg, −19.5% with 10 mg, and −20.9% with 15 mg of tirzepatide, compared with −3.1% on placebo.What they found At 72 weeks, the mean weight change was −15.0% with 5 mg, −19.5% with 10 mg, and −20.9% with 15 mg of tirzepatide, compared with −3.1% on placebo. The response was clearly dose-dependent, and even the lowest dose far exceeded the placebo effect of diet and exercise counseling alone. Outcome at 72 weeks · Tirzepatide 5 mg · Tirzepatide 10 mg · Tirzepatide 15 mg · Placebo Mean weight change · −15.0% · −19.5% · −20.9% · −3.1% ≥5% weight loss · 85% · 89% · 91% · 35% Discontinuation due to adverse events · 4.3% · 7.1% · 6.2% · 2.6%

#24
fda.gov 2023-11-08 | FDA Approves New Medication for Chronic Weight Management

These studies measured weight reduction after 72 weeks in a total of 2,519 patients who received either 5 mg, 10 mg or 15 mg of Zepbound once weekly and a total of 958 patients who received once-weekly placebo injections. In both trials, after 72 weeks of treatment, patients who received Zepbound at all three dose levels experienced a statistically significant reduction in body weight compared to those who received placebo, and greater proportions of patients who received Zepbound achieved at least 5% weight reduction compared to placebo. The larger of the two trials enrolled adults without diabetes. At the start of the trial, the average body weight was 231 pounds (105 kg) and average body mass index was 38 kg/m2. In this trial, those randomized to receive the highest approved dosage of Zepbound (15 mg once weekly) lost on average 18% of their body weight compared to those randomized to placebo.… The maximum dosage of Zepbound is 15 mg once weekly. Zepbound’s effectiveness for chronic weight management (weight reduction and maintenance) in combination with a reduced-calorie diet and increased physical activity was established in two randomized, double-blind, placebo-controlled trials of adults with obesity or overweight with at least one weight-related condition. These studies measured weight reduction after 72 weeks in a total of 2,519 patients who received either 5 mg, 10 mg or 15 mg of Zepbound once weekly and a total of 958 patients who received once-weekly placebo injections. In both trials, after 72 weeks of treatment, patients who received Zepbound at all three dose levels experienced a statistically significant reduction in body weight compared to those who received placebo, and greater proportions of patients who received Zepbound achieved at least 5% weight reduction compared to placebo. The larger of the two trials enrolled adults without diabetes. At the start of the trial, the average body weight was 231 pounds (105 kg) and average body mass index was 38 kg/m2. In this trial, those randomized to receive the highest approved dosage of Zepbound (15 mg once weekly) lost on average 18% of their body weight compared to those randomized to placebo. At the start of the trial in adults with type 2 diabetes, the average body weight was 222 pounds (101 kg) and average body mass index was 36 kg/m2. Those randomized to receive the highest approved dosage of Zepbound (15 mg once weekly) lost on average 12% of their body weight compared to those randomized to placebo.

#25
healthrx.com 2026-05-25 | SURMOUNT-1 Results in Detail: Numbers, Subgroups, and Time Course

HealthRX.com quick answer. Tirzepatide 15 mg produced a mean 20.9% body weight reduction at 72 weeks versus 3.1% with placebo in SURMOUNT-1 (N = 2,539). … Key result: −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg) vs −3.1% (placebo); all p <0.0015 linked public sources · Editorial, sourcing, and corrections policy HealthRX.com quick answer. Tirzepatide 15 mg produced a mean 20.9% body weight reduction at 72 weeks versus 3.1% with placebo in SURMOUNT-1 (N = 2,539). More than one in three participants on the highest dose lost at least 25% of their body weight. The dose-response relationship was consistent, and weight was still declining at week 72, suggesting the full efficacy ceiling had not been reached. At a glance - Trial name: SURMOUNT-1 (NCT04184622) - N: 2,539 adults with BMI ≥30 (or ≥27 with comorbidity), without diabetes - Intervention: Tirzepatide 5 mg, 10 mg, or 15 mg subcutaneous once weekly - Comparator: Matched placebo - Duration: 72 weeks (including 20-week dose escalation) - Primary endpoint: Percent change in body weight from baseline to week 72 - Key result: −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg) vs −3.1% (placebo); all p <0.001 What the Primary Endpoint Actually Showed

#26
journaljams.org Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

At week 72, the mean percentage change in body weight was -15.0% for the 5-mg dose, -19.5% for the 10-mg dose, and -20.9% for the 15-mg dose, compared with -3.1% for placebo (P<0.001 for all comparisons).1. At baseline, the 2,539 participants had a mean body weight of 104.8 kg and a mean BMI of 38.0, with 94.5% having a BMI of 30 or higher [4.1.6]. 2. At week 72, the mean percentage change in body weight was -15.0% for the 5-mg dose, -19.5% for the 10-mg dose, and -20.9% for the 15-mg dose, compared with -3.1% for placebo (P<0.001 for all comparisons). 3. A weight reduction of 5% or more was achieved by 85%, 89%, and 91% of participants receiving 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, versus 35% in the placebo group.

#27
patientcareonline.com 2022-04-28 | Tirzepatide Yields Top Weight Loss of 20% or More in SURMOUNT Clinical ...

SURMOUNT-1 was a multicenter, randomized, double-blind, parallel, placebo-controlled trial comparing the efficacy and safety of tirzepatide at doses of 5 mg, 10 mg, and 15 mg to placebo as an adjunct to diet and physical activity in 2539 adults without T2D with obesity or overweight and 1 of the prespecified comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. … Lilly reports in its release the following for treatment with tirzepatide vs placebo:Tirzepatide has demonstrated efficacy in and is currently under regulatory review for treatment of type 2 diabetes- (T2D) related hyperglycemia. SURMOUNT-1 is the first phase 3 global registration trial to evaluate the new agent’s safety and efficacy in adults without T2D who have obesity or overweight with at least one comorbidity, according to the statement. SURMOUNT-1 was a multicenter, randomized, double-blind, parallel, placebo-controlled trial comparing the efficacy and safety of tirzepatide at doses of 5 mg, 10 mg, and 15 mg to placebo as an adjunct to diet and physical activity in 2539 adults without T2D with obesity or overweight and 1 of the prespecified comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. All patients began treatment at the 2.5 mg weekly dose and were titrated at 4-week intervals to the final randomized doses. Lilly reports in its release the following for treatment with tirzepatide vs placebo: Reporting on safety of tirzepatide, the company notes the most commonly reported adverse events were gastrointestinal-related, as is common with the class, and were generally mild to moderate in severity, with most occurring during the dose-escalation period of the trial.

- 2539 patients were randomly assigned in a 1:1:1:1 ratio to receive Mounjaro at a dose of 5 mg, 10 mg, or 15mg or placebo, administered subcutaneously once weekly for 72 weeks as an adjunct to lifestyle intervention. … Percentage change in body weight over time from baseline to week 72 (Efficacy estimand) 22.5 average reduction in body weight With Mounjaro 15mg at 72 weeks★ SURMOUNT-1 Trial Design - 2539 patients were randomly assigned in a 1:1:1:1 ratio to receive Mounjaro at a dose of 5 mg, 10 mg, or 15mg or placebo, administered subcutaneously once weekly for 72 weeks as an adjunct to lifestyle intervention. - Participants: Adults (18 years of age or older), with a body-mass index (BMI) of 30 or more, or a BMI of 27 or more and at least one weight-related complication (e.g. hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease), and who reported one or more unsuccessful dietary effort to lose weight. CO-PRIMARY ENDPOINTS (10 mg and/or 15mg) … - Percentage change in weight from baseline at week 72. - Percentage of population with Weight Reductions of ≥5% at week 72. Percentage change in body weight over time from baseline to week 72 (Efficacy estimand) 22.5 average reduction in body weight With Mounjaro 15mg at 72 weeks p<0.001 vs placebo, adjusted for multiplicity. Efficacy estimand, MMRM analysis. Studied in adults with obesity (BMI of ≥30 kg/m²) or with overweight (BMI of ≥27 kg/m²) with at least 1 weight-related complication, excluding type 2 diabetes. All participants received lifestyle intervention, including a reduced-calorie diet and increased physical activity. BMI=body mass index; mITT=modified intent-to-treat; MMRM=mixed model for repeated measures.

#29
jtojjar.com SURMOUNT-1: How to Read a Weight-Loss Trial | Jasaman Tojjar

Mean weight change at 72 weeks was about -15.0%, -19.5%, and -20.9% across ascending dose groups versus -3.1% with placebo under the headline treatment-regimen analysis. … In the primary report, estimated mean changes under the treatment-regimen estimand were -15.0%, -19.5%, and -20.9% in the active groups and -3.1% with placebo.Evidence takeaways - [SURMOUNT-1](https://www.nejm.org/doi/10.1056/NEJMoa2206038) randomized 2,539 adults with obesity or overweight plus a weight-related complication, excluding diabetes, to three tirzepatide groups or placebo for 72 weeks. - Mean weight change at 72 weeks was about -15.0%, -19.5%, and -20.9% across ascending dose groups versus -3.1% with placebo under the headline treatment-regimen analysis. - An estimand specifies the treatment effect being asked about, including what to do after discontinuation or other events. Different estimands can be valid while answering different questions. - Gastrointestinal adverse events were common, and more participants stopped treatment because of adverse events in active groups than with placebo. … The continuous outcome shows average magnitude. The threshold outcome shows how many crossed a clinically recognizable boundary. Neither reveals the whole distribution. Two groups can have the same mean while one has tightly clustered responses and another has a mix of large loss, little change, and discontinuation. In the primary report, estimated mean changes under the treatment-regimen estimand were -15.0%, -19.5%, and -20.9% in the active groups and -3.1% with placebo. At least 5% loss was estimated in 85%, 89%, and 91% versus 35%. At least 20% loss occurred in 50% and 57% of the two higher-dose groups versus 3% with placebo; the lowest-dose group was not included in that particular multiplicity-tested comparison. These are model-based group estimates with confidence intervals, not promises. A 20% mean reduction does not mean that each participant lost 20% or that every kilogram was fat rather than lean tissue.

Debate

Two AI advocates debated this claim using the research gathered.

Argument for

P
Proponent Argues TRUE

SURMOUNT-1 definitively recorded a mean 20.9% weight reduction at week 72 for once-weekly tirzepatide, as independently documented in the peer-reviewed NEJM report (Source 1) and FDA labeling (Source 2). The trial's dose-specific reporting establishes that this 20.9% figure pertains to the 15-mg arm; nevertheless, the stated week, outcome, and once-weekly tirzepatide context are directly supported by Sources 1 and 2.

O
Opponent Rebuttal

The Proponent concedes that the -20.9% figure belongs to the 15-mg arm, which is dispositive because the claim explicitly assigns it to 5 mg, where Sources 1, 2 and 4 all report -15.0%; partial credit for the correct week and outcome cannot rescue a figure attached to the wrong dose. The Proponent also commits a fallacy of equivocation by treating 'once-weekly tirzepatide' generically, when the claim specifies a dose and SURMOUNT-1 reported dose-specific results that differ by nearly six percentage points between 5 mg and 15 mg (Source 2, Table 2; Source 4, Table 14).

Argument against

O
Opponent Argues FALSE

The claim misattributes the figure: the -20.9% mean change at week 72 belongs to the 15 mg arm, whereas the 5 mg arm achieved only -15.0% (Source 1, NEJM; Source 2, FDA label; Source 4, FDA Statistical Review Table 14). Because every authoritative source shows -15.0% for 5 mg and -20.9% for 15 mg, the claim attaches the number to the wrong dose and is therefore false as stated.

P
Proponent Rebuttal

The Opponent correctly identifies the dose-specific result but thereby confirms the claim's core reported figure, timing, trial, and once-weekly tirzepatide context: the authoritative record states −20.9% at week 72 for the 15-mg arm (Source 1, New England Journal of Medicine; Source 2, FDA label). The Opponent's conclusion depends on treating a dose-labeling defect as negating the underlying trial result, despite Sources 1, 2, and 4 explicitly establishing that 5 mg produced −15.0% and 15 mg produced −20.9%.

Panel Review

3 reviewers assessed the evidence and the arguments.

Reviewer A · Claude

False
1/10

The NEJM report (Source 1), the FDA label (Source 2) and the FDA statistical review (Source 4) all report a mean change of -15.0% at week 72 for 5 mg tirzepatide. The -20.9% figure belongs to the 15 mg arm. Sources 3, 5, 6, 7 and many others agree. The claim names the 5 mg dose explicitly, so it attaches the figure to the wrong arm. The trial, week and measure are right, but the dose is the central detail. The Proponent concedes this misattribution. The claim is false.

Precision issues

  • The claim attributes the 15 mg arm's -20.9% result to the 5 mg arm, whose reported result is -15.0%.

Reviewer B · GPT

False
1/10

The peer-reviewed SURMOUNT-1 report states that the mean percentage change at week 72 was −15.0% for once-weekly 5 mg tirzepatide and −20.9% for 15 mg, directly contradicting the claim's dose-specific figure [1]. The FDA label and FDA statistical review independently record the same 5-mg result of −15.0% and distinguish it from the −20.9% result for 15 mg [2, 4]. These sources address the exact trial, week, outcome, and dose, so the claim materially misattributes the result. The claim is False.

Source issues

  • Sources 1, 2, and 4 concern the same underlying SURMOUNT-1 trial, so they are not independent clinical replications.

Precision issues

  • The claim assigns the −20.9% mean weight change to the 5-mg dose, but the cited records assign that figure to 15 mg and report −15.0% for 5 mg.

Reviewer C · Gemini

False
2/10

Reliable clinical trial publications and regulatory records directly examine the weight loss outcomes of the Phase 3 SURMOUNT-1 trial (Sources 1, 2, 4). These sources conclusively demonstrate that at week 72, the mean percentage change in body weight was -15.0% for once-weekly 5 mg tirzepatide, whereas -20.9% was observed only for the 15 mg dose. Because the claim explicitly pairs the 5 mg dose with the outcome belonging to the 15 mg dose, it materially misstates the efficacy of that specific dosage, rendering it false.

Precision issues

  • The claim incorrectly attributes the -20.9% mean weight loss observed with the 15 mg dose to the 5 mg dose, which achieved -15.0%.

Panel summary

The peer-reviewed SURMOUNT-1 publication, the FDA label revised in January 2026, and the FDA statistical review directly address the named trial, dose, endpoint, and time point. All report −15.0% mean body-weight change for once-weekly 5 mg tirzepatide at week 72 and assign −20.9% to the 15 mg arm. The evidence consistently identifies a dose-specific misattribution, with no substantive disagreement. Although the trial name, timing, and outcome measure are correct, assigning another dose's result to 5 mg materially misstates its efficacy and supports the False verdict.

See the full panel summary

Create a free account to read the complete analysis.

Sign up free
The claim is
False
Score: 1/10
Confidence: 9/10 Spread: 1 pt

Only you will see this note.

Embed this verification

Every embed carries schema.org ClaimReview microdata — recognized by Google and AI crawlers.

False · Lenz Score 1/10 Lenz
“At week 72 of the Phase 3 SURMOUNT-1 trial, the mean percentage change in body weight was -20.9% with once-weekly 5 mg tirzepatide.”
29 sources · 3-panel audit
See full report on Lenz →